drugset / Trial / NCT02253394
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps every minute), right ventricle function and quality of life.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Spironolactone | Small molecule | 50 mg | — |
| Comparator | Ambrisentan | Small molecule | 5 mg | — |
| Comparator | Ambrisentan | Small molecule | 10 mg | — |